Navigation Links
Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
Date:7/10/2008

ANTONY, France, July 10 /PRNewswire-FirstCall/ --

- 1st Half-Year Sales Up 16%

- Revision Upwards of 2008 Sales Growth Guidance: (greater than or equal to)12%

EUR millions 2006 2007 07/06 2008 08/07

EURM %Sales EURM %Sales % EURM %Sales %

change change

Southern Europe (1) 20.5 72 23.2 72 13 26.8 71 15

Other EU countries (2) 6.9 24 7.7 24 11 9.3 24 20

Other markets 1.2 4 1.3 4 15 2.0 5 47

SLIT 21.8 76 25.1 77 15 30.4 80 21

SCIT 5.4 19 5.6 18 5 6.1 16 7

Other products 1.5 5 1.5 5 (0) 1.6 4 4

Total Q2 sales 28.6 100 32.2 100 13 38.0 100 18

Southern Europe (1) 48.1 75 56.5 76 18 64.7 75 14

Other EU countries (2) 13.7 21 15.8 21 15 18.6 21 18

Other markets 2.4 4 2.5 3 5 3.7 4 46

SLIT 49.4 77 59.7 80 21 71.3 82 19

SCIT 11.6 18 11.8 16 2 12.3 14 4

Other products 3.2 5 3.2 4 3 3.4 4 6

Total H1 sales 64.2 100 74.8 100 17 87.0 100 16

(1) Portugal, Spain, France, Italy, Greece; (2) Switzerland included

2008 second quarter sales recorded strong growth in all markets (+18% vs +13% in 2007). Eastern European markets and other markets outside Europe made a significant contribution to this growth. The most buoyant segment of the market remained desensitisation via the sublingual route (SLIT, +21%, vs +15% in 2007) whose reputation was enhanced by the launch of allergen tablets.

Cumulated sales for the first half-year increased by 16% compared to the first half 2007, when growth was already particularly strong (+ 17%). This good performance has enabled the Group to revise its sales growth guidance upwards to growth of at least 12% in 2008 (vs (greater than or equal to)10% previously), boosted by the growing success of the sublingual route, in which Stallergenes continues to strengthen its leadership.

The commercial launch of ORALAIR(R) Grasses for adults will take place in Germany in the next few weeks, following the grant, on 24 June 2008, of the marketing authorisation. The request for a paediatric extension of ORALAIR(R) Grasses has been filed with the Paul Ehrlich Institute. The application for clinical studies for ORALAIR(R) Grasses in the US will be filed in July.

The 2008 first half-year financial results will benefit from a strong level of activity and will show a marked improvement compared to 2007. These results will be released on 27 August 2008.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitisation therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitisation treatment, Stallergenes devotes 16% of its turnover to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitisation tablets.

In 2007, Stallergenes had a turnover of 147 million euros and provided desensitisation treatments to more than 500,000 patients.

Stallergenes is listed in Euronext Paris (Compartment B) and

is part of the sample composing the SBF 120 index.

ISIN Code: FR0000065674

Reuters Code: GEN.PA

Bloomberg Code: GEN.FP

Additional information is available on http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
2. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
3. Pinnacle Biologics Announces Agreement With pharmexx to Expand Sales Support Activities in Key European Markets
4. Ovalum Ltd. Announces Sales Launch of CiTop™ Product-Line in Europe
5. Hoviones Sales Grow 11%
6. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
7. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
8. Increasing Sales Productivity Through Superior Sales Force Performance Management
9. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
10. Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales
11. Direct Medical Systems Reaches Profitability in 2-1/2 Years, as a Result of Sales of the Worlds Smallest and Lightest Ultrasound System, the InNovaSound USB Ultrasound.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry ... Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s mission ... hardware projects are designed, built and brought to market. , The Design Lab ...
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining ... Chicago. The result of a collaboration among several companies with expertise in toolholding, ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:6/1/2016)... Favorable Government Initiatives Coupled With ... Identification to Boost Global Biometrics System Market Through 2021  ... report, " Global Biometrics Market By Type, By ... 2011 - 2021", the global biometrics market is projected ... of growing security concerns across various end use sectors ...
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
Breaking Biology News(10 mins):